Article Sidebar
Main Article Content
WISP1 Inhibits Hepatocellular Carcinoma Cell Proliferation by Promoting CyclinD1 Ubiquitination and Downregulating its Expression
Main Article Content
Abstract
Background/Aims: Hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths, is often linked to dysregulated cell cycle proteins. This study focuses on the role of WISP1 in modulating Cyclin D1, a key cell cycle regulator, in HCC.
Materials and Methods: The study used HCCLM3 and Hep3B cells to assess the expression of Cyclin D1 and cell proliferation following the treatment of WISP1. This was achieved through Western blot, qRT-PCR, and EdU assays. Additionally, animal studies were conducted to evaluate the effects of WISP1 treatment on Cyclin D1 expression and cell proliferation.
Results: Overexpression of WISP1 in HCC cells led to a marked decrease in Cyclin D1 protein levels and reduced cell proliferation. WISP1 influences Cyclin D1 through post-translational modifications, particularly ubiquitination and proteasomal degradation.
Conclusion: The findings revealed that WISP1’s modulation of Cyclin D1 plays a critical role in inhibiting HCC cell growth, highlighting a potential therapeutic target for HCC treatment.
Cite this article as: Yan J, wen Hu J, Lei J, et al. WISP1 inhibits hepatocellular carcinoma cell proliferation by promoting CyclinD1 ubiquitination and downregulating its expression. Turk J Gastroenterol. 2025;36(4):247-254.
Article Details
References
1. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864-884. [CrossRef]
2. Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis. 2013;33(suppl 1):S11-S19. [CrossRef]
3. Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 2018;12:9-26. [CrossRef]
4. Katoh M, Katoh M. Wnt signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13(14):4042-4045. [CrossRef]
5. Perbal A, Perbal B. The CCN family of proteins: a 25th anniversary picture. J Cell Commun Signal. 2016;10(3):177-190. [CrossRef]
6. Wu YL, Li HY, Zhao XP, et al. Mesenchymal stem cell-derived CCN2 promotes the proliferation, migration and invasion of human tongue squamous cell carcinoma cells. Cancer Sci. 2017;108(5):897-909. [CrossRef]
7. Wu J, Long Z, Cai H, et al. High expression of WISP1 in colon cancer is associated with apoptosis, invasion and poor prognosis. Oncotarget. 2016;7(31):49834-49847. [CrossRef]
8. Wang J, Zhang GY, Li XH. Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells. Chin J Dig Dis. 2006;7(4):219-224. [CrossRef]
9. Shao H, Cai L, Grichnik JM, et al. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene. 2011;30(42):4316-4326. [CrossRef]
10. Soon LL, Yie TA, Shvarts A, et al. Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem. 2003;278(13):11465-11470. [CrossRef]
11. Davies SR, Watkins G, Mansel RE, et al. Differential expression and prognostic implications of the CCN family members WISP1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol. 2007;14(6):1909-1918. [CrossRef]
12. Yan J, Lei J, Chen L, et al. Human leukocyte antigen F Locus adjacent Transcript 10 overexpression disturbs WISP1 protein and mRNA expression to promote hepatocellular carcinoma progression. Hepatology. 2018;68(6):2268-2284. [CrossRef]
13. Chalermrujinanant C, Michowski W, Sittithumcharee G, et al. Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation. Oncogene. 2016;35(22):2815-2823. [CrossRef]
14. Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016;94(12):1313-1326. [CrossRef]
15. Yuan C, Zhu X, Han Y, et al. Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1. J Exp Clin Cancer Res. 2016;35:15. [CrossRef]
16. Li X, Gong X, Chen J, et al. miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res Commun. 2015;460(3):670-677. [CrossRef]
17. Tu K, Liu Z, Yao B, et al. BCL-3 promotes the tumor growth of hepatocellular carcinoma by regulating cell proliferation and the cell cycle through cyclin D1. Oncol Rep. 2016;35(4):2382-2390. [CrossRef]
18. Liu J, Cui X, Qu L, et al. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. Exp Mol Pathol. 2016;101(1):58-65. [CrossRef]
19. Qiu Y, Huang D, Sheng Y, et al. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1. Exp Cell Res. 2021;405(1):112646. [CrossRef]
20. Zhang S, Li N, Sheng Y, et al. Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. Infect Agent Cancer. 2021;16(1):20. [CrossRef]
21. Yang X, Feng Y, Liu Y, et al. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 2021;87:153575. [CrossRef]
22. Brown JL, Lee DE, Rosa-Caldwell ME, et al. Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2018;9(5):987-1002. [CrossRef]
23. Maimaiti Y, Kamali A, Yang P, et al. Hsa_circ_0008092 contributes to cell proliferation and metastasis in hepatocellular carcinoma via the miR-502-5p/CCND1 axis. Protein Pept Lett. 2022;29(7):595-604. [CrossRef]
24. Hamada T, Akahane T, Yokoyama S, et al. An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors. Sci Rep. 2022;12(1):1275. [CrossRef]
25. Ferrand N, Béreziat V, Moldes M, et al. WISP1/CCN4 inhibits adipocyte differentiation through repression of PPARγ activity. Sci Rep. 2017;7(1):1749. [CrossRef]